Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-12-2018 | Review – Cancer Research

The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2018

Abstract

Purpose

The okadaic acid class of tumor promoters, which are inhibitors of protein phosphatases 1 and 2A (PP1 and PP2A), induced tumor promotion in mouse skin, rat glandular stomach, and rat liver. Endogenous protein inhibitors of PP2A, SET and CIP2A, were up-regulated in various human cancers, so it is vital to review the essential mechanisms of tumor promotion by the okadaic acid class compounds, together with cancer progression by SET and CIP2A in humans.

Results and discussion

The first part of this review introduces the okadaic acid class compounds and the mechanism of tumor promotion: (1) inhibition of PP1 and PP2A activities of the okadaic acid class compounds; (2) some topics of tumor promotion; (3) TNF-α gene expression as a central mediator in tumor promotion; (4) exposure to the okadaic acid class of tumor promoters in relation to human cancer. The second part emphasizes the overexpression of SET and CIP2A in cancer progression, and the anticancer activity of SET antagonists as follows: (5) isolation and characterization of SET; (6) isolation and characterization of CIP2A; (7) progression of leukemia with SET; (8) progression of breast cancer with SET and CIP2A; (9) progression of lung cancer with SET; (10) anti-carcinogenic effects of SET antagonists OP449 and FTY720; and also (11) TNF-α-inducing protein of Helicobacter pylori, which is a clinical example of the okadaic acid pathway.

Conclusions

The overexpression of endogenous protein inhibitors of PP2A, SET and CIP2A, is tightly linked to the progression of various human cancers, as well as Alzheimer’s disease.

Adachi Y, Pavlakis GN, Copeland TD (1994) Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 269:2258–2262PubMed

Agarwal A et al (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 20:2092–2103CrossRef

Amick GD, Reddy SA, Damuni Z (1992) Protein phosphatase 2A is a specific protamine-kinase-inactivating phosphatase. Biochem J 287:1019–1022CrossRef

Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C (2012) CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 13:289–295CrossRef

Brautigan DL, Shriner CL (1988) Methods to distinguish various types of protein phosphatase activity. Methods Enzymol 159:339–346CrossRef

Carmichael WW et al (1988) Naming of cyclic heptapeptide toxins of cyanobacteria (blue-green algae). Toxicon 26:971–973CrossRef

Christensen DJ et al (2011a) SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 118:4150–4158. https://doi.org/10.1182/blood-2011-04-351072 CrossRefPubMedPubMedCentral

Christensen DJ et al (2011b) Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 186:2535–2542CrossRef

Côme C et al (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15:5092–5100CrossRef

Cristóbal I et al (2014) PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 13:938–947CrossRef

Erdödi F, Rokolya A, Di Salvo J, Bárány M, Bárány K (1988) Effect of okadaic acid on phosphorylation-dephosphorylation of myosin light chain in aortic smooth muscle homogenate. Biochem Biophys Res Commun 153:156–161CrossRef

Fujiki H (2014) Gist of Dr. Katsusaburo Yamagiwa’s papers entitled “Experimental study on the pathogenesis of epithelial tumors” (I to VI reports). Cancer Sci 105:143–149CrossRef

Fujiki H, Suganuma M (1993) Tumor promotion by inhibitors of protein phosphatases 1 and 2A: the okadaic acid class of compounds. Adv Cancer Res 61:143–194CrossRef

Fujiki H, Suganuma M (2005) Translational research on TNF-α as an endogenous tumor promoter and green tea as cancer preventive in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 23:3–30PubMed

Fujiki H et al (1995) Tumor promotion and prevention of stomach cancer. In: Nishi M, Sugano H, Takahashi T (eds) International gastric cancer congress. Monduzzi Editore, SpA Bologna, Italy, pp 19–25

Fujiki H, Watanabe T, Suganuma M (2014) Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 140:689–699CrossRef

Goerttler K, Loehrke H, Schweizer J, Hesse B (1980) Two-stage skin carcinogenesis by systemic initiation of pregnant mice with 7,12-dimethylbenz(a)anthracene during gestation days 6–20 and postnatal promotion of the F 1-generation with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. J Cancer Res Clin Oncol 98:267–275CrossRef

Guy GR, Cao X, Chua SP, Tan YH (1992) Okadaic acid mimics multiple changes in early protein phosphorylation and gene expression induced by tumor necrosis factor or interleukin-1. J Biol Chem 267:1846–1852PubMed

Hecker E et al (1967) Structure and stereochemistry of the tetracyclic diterpene phorbol from Croton tiglium L. Tetrahedron Lett 8:3165–3170CrossRef

Hecker E, Adolf W, Hergenhahn R, Schmidt R, Sorg B (1984) Irritant diterpene ester promoters of mouse skin:contributions to etiologies of environmental cancer and to biochemical mechanisms of carcinogenesis. In: Fujiki H, Hecker E, Moore RE, Sugimura T, Weinstein IB (eds) Cellular interactions by environmental tumor promoters. Jpn Sci Soc Press/VNU Science Press, BV, Tokyo/Utrecht, pp 3–36

Hescheler J, Mieskes G, Rüegg JC, Takai A, Trautwein W (1988) Effects of a protein phosphatase inhibitor, okadaic acid, on membrane currents of isolated guinea-pig cardiac myocytes. Pflugers Arch 412:248–252CrossRef

IARC Working Group on the Evaluation of Carcinogenesis Risks to Humans (1994) Infection with Helicobacter pylori. In: IARC monographs on the evaluation of carcinogenic risks to humans. IARC Lyon 61:177–220

Ingebritsen TS (1991) Resolution and characterization of multiple protein-tyrosine phosphatase activities. Methods Enzymol 201:451–465CrossRef

Janghorban M et al (2014) Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA 111:9157–9162CrossRef

Junttila MR et al (2007) CIP2A inhibits PP2A in human malignancies. Cell 130:51–62CrossRef

Kato Y, Fusetani N, Matsunaga S, Hashimoto K, Fujita S, Furuya TJ (1986) Calyculin A, a novel antitumor metabolite from the marine sponge Discodermia calyx. J Am Chem Soc 108:2780–2781CrossRef

Kellogg EH, Hejab NMA, Poepsel S, Downing KH, DiMaio F, Nogales E (2018) Near-atomic model of microtubule-tau interactions. Science 360:1242–1246CrossRef

Kitagawa T, Kayano T, Mikami K, Watanabe R, Sugano H (1984) Promotion of hepatocarcinogenesis in vivo and in vitro. In: Fujiki H, Hecker E, Moore RE, Sugimura T, Weinstein IB (eds) Cellular interactions by environmental tumor promoters. Jpn Sci Soc Press/VNU Science Press, BV, Tokyo/Utrecht, pp 337–348

Li M, Guo H, Damuni Z (1995) Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34:1988–1996CrossRef

Li M, Makkinje A, Damuni Z (1996) The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271:11059–11062CrossRef

Li J et al (2014) Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion. Biochem Biophys Res Commun 453:7–12CrossRef

Liu H et al (2015) Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget 6:14913–14925PubMedPubMedCentral

Marino MW et al (1997) Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 94:8093–8098CrossRef

Murata M, Shimatani M, Sugitani H, Oshima Y, Yasumoto T (1982) Isolation and structural elucidation of the causative toxin of the diarrhetic shellfish poisoning. Bull Jpn Soc Sci Fish 48:549–552CrossRef

Nishiwaki S, Fujiki H, Suganuma M, Ojika M, Yamada K, Sugimura T (1990) Photoaffinity labeling of protein phosphatase 2A, the receptor for a tumor promoter okadaic acid, by [27-³H]methyl 7-O-(4-azidobenzoyl)okadaate. Biochem Biophys Res Commun 170:1359–1364CrossRef

Nishiwaki-Matsushima R et al (1992) Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR. J Cancer Res Clin Oncol 118:420–424CrossRef

Oaks JJ et al (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122:1923–1934CrossRef

Ohta T et al (1994) Nodularin, a potent inhibitor of protein phosphatases 1 and 2A, is a new environmental carcinogen in male F344 rat liver. Cancer Res 54:6402–6406PubMed

Park TJ, Song KY, Sohn SH, Lim IK (2002) Marked inhibition of testosterone biosynthesis by the hepatotoxin nodularin due to apoptosis of Leydig cells. Mol Carcinog 34:151–163CrossRef

Rinehart KL et al (1988) Nodularin, microcystin, and the configuration of Adda. J Am Chem Soc 110:8557–8558CrossRef

Sato K, Kitahara A, Satoh K, Ishikawa T, Tatematsu M, Ito N (1984) The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gan 75:199–202PubMed

Schmouder R, Hariry S, David OJ (2012) Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol 68:355–362CrossRef

Shentu YP et al (2018) CIP2A causes Tau/APP phosphorylation, synaptopathy, and memory deficits in Alzherimer’s disease. Cell Rep 24:713–723CrossRef

Shibata S, Ishida Y, Kitano H, Ohizumi Y, Habon J, Tsukitani Y, Kikuchi H (1982) Contractile effects of okadaic acid, a novel ionophore-like substance from black sponge, on isolated smooth muscles under the condition of Ca deficiency. J Pharmacol Exp Ther 223:135–143PubMed

Soo Hoo L, Zhang JY, Chan EK (2002) Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene 21:5006–5015CrossRef

Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J 13:1911–1922CrossRef

Sueoka E et al (1997) Expression of the tumor necrosis factor-α gene and early response genes by nodularin, a liver tumor promoter, in primary cultured rat hepatocytes. J Cancer Res Clin Oncol 123:413–419PubMed

Suganuma M, Fujiki H, Morino K, Takayama S, Sugimura T (1987) Tumor promoting activity of teleocidin in skin and forestomach of mice initiated transplacentally with 7,12-dimethylbenz(a)anthracene. J Cancer Res Clin Oncol 113:123–125CrossRef

Suganuma M et al (1988) Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci USA 85:1768–1771CrossRef

Suganuma M, Suttajit M, Suguri H, Ojika M, Yamada K, Fujiki H (1989) Specific binding of okadaic acid, a new tumor promoter in mouse skin. FEBS Lett 250:615–618CrossRef

Suganuma M, Fujiki H, Okabe S, Nishiwaki S, Brautigan D, Ingebritsen TS, Rosner MR (1992a) Structurally different members of the okadaic acid class selectively inhibit protein serine/threonine but not tyrosine phosphatase activity. Toxicon 30:873–878CrossRef

Suganuma M, Tatematsu M, Yatsunami J, Yoshizawa S, Okabe S, Uemura D, Fujiki H (1992b) An alternative theory of tissue specificity by tumor promotion of okadaic acid in glandular stomach of SD rats. Carcinogenesis 13:1841–1845CrossRef

Suganuma M, Yatsunami J, Yoshizawa S, Okabe S, Fujiki H (1993) Absence of synergistic effects on tumor promotion in CD-1 mouse skin by simultaneous applications of two different types of tumor promoters, okadaic acid and teleocidin. Cancer Res 53:1012–1016PubMed

Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor-α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 59:4516–4518PubMed

Suganuma M, Kurusu M, Okabe S, Sueoka N, Yoshida M, Wakatsuki Y, Fujiki K (2001) Helicobacter pylori membrane protein 1: a new carcinogenic factor of Helicobacter pylori. Cancer Res 61:6356–6359PubMed

Suganuma M et al (2002) Discrete roles of cytokines, TNF-α, IL-1, IL-6 in tumor promotion and cell transformation. Int J Oncol 20:131–136PubMed

Suganuma M, Kurusu M, Suzuki K, Nishizono A, Murakami K, Fujioka T, Fujiki H (2005) New tumor necrosis factor-α-inducing protein released from Helicobacter pylori for gastric cancer progression. J Cancer Res Clin Oncol 131:305–313CrossRef

Suganuma M et al (2008) TNF-α-inducing protein, a carcinogenic factor secreted from H. pylori, enters gastric cancer cells. Int J Cancer 123:117–122CrossRef

Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP (2011) Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30:2504–2513CrossRef

Tachibana K et al (1981) Okadaic acid, a cytotoxic polyether from two marine sponges of the genes Halichondria. J Am Chem Soc 103:2469–2471CrossRef

Takashima M, Sakai H (1960) A new toxic substance, teleocidin, produced by Streptomyces. Part I. Production, isolation and chemical studies. Bull Agr Chem Soc Jpn 24:647–651

Tanimukai H, Grundke-Iqbal I, Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease. Am J Pathol 166:1761–1771CrossRef

von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A, Grosveld G (1992a) The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 12:1687–1697CrossRef

von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G (1992b) Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol 12:3346–3355CrossRef

Watanabe T et al (2010a) Nucleolin as cell surface receptor for tumor necrosis factor-α-inducing protein: a carcinogenic factor of Helicobacter pylori. J Cancer Res Clin Oncol 136:911–921CrossRef

Watanabe T. Hirano K. Takahashi A. Yamaguchi K. Beppu M. Fujiki H. Suganuma M (2010b) Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol Pharm Bull 33:796–803CrossRef

Watanabe T, Takahashi A, Suzuki K, Kurusu-Kanno M, Yamaguchi K, Fujiki H, Suganuma M (2014) Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-α-inducing protein of Helicobacter pylori. Int J Cancer 134:2373–2382CrossRef

Yamagiwa K, Ichikawa K (1915) Experimentelle Studie über die Pathogenese der Epithelialgeschwülste. (I Mitteilungen) Mitteil Med Fakultät. Kaiserl Univ Tokyo 15:295–344

Yasumoto T, Murata M, Oshima Y, Sano M, Matsumoto GK, Clardy J (1985) Diarrhetic shellfish toxins. Tetrahedron 41:1019–1025CrossRef

Yoshida M et al (1999) Cloning and characterization of a novel membrane-associated antigenic protein of Helicobacter pylori. Infect Immun 67:286–293PubMedPubMedCentral

Yoshizawa S, Matsushima R, Watanabe MF, Harada K, Ichihara A, Carmichael WW, Fujiki H (1990) Inhibition of protein phosphatases by microcystins and nodularin associated with hepatotoxicity. J Cancer Res Clin Oncol 116:609–614CrossRef

Yuasa H, Yoshida K, Iwata H, Nakanishi H, Suganuma M, Tatematsu M (1994) Increase of labeling indices in gastrointestinal mucosae of mice and rats by compounds of the okadaic acid type. J Cancer Res Clin Oncol 120:208–212CrossRef

Title: The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers
Publication date: 01-12-2018
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2765-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers

Abstract

Purpose

Results and discussion

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Results and discussion

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2018

Presence and activity of HPV in primary lung cancer

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

Kaposiform hemangioendothelioma without cutaneous involvement

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance

Progress in gene therapy using oncolytic vaccinia virus as vectors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page